RT Journal Article
T1 PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.
A1 Peg, Vicente
A1 López-García, María Ángeles
A1 Comerma, Laura
A1 Peiró, Gloria
A1 García-Caballero, Tomás
A1 López, Ángel Concha
A1 Suárez-Gauthier, Ana
A1 Ruiz, Irune
A1 Rojo, Federico
K1 PD-L1
K1 antibody
K1 breast cancer
K1 diagnosis
K1 immunohistochemistry
K1 immunotherapy
AB Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.
YR 2020
FD 2020-12-08
LK http://hdl.handle.net/10668/16754
UL http://hdl.handle.net/10668/16754
LA en
DS RISalud
RD Mar 14, 2025